Payment overview · 2025
General Payments
$1,070.75
40 reported records · 22 companies
Healthcare provider profile · identity verified
Aureliano E Cifuentes, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TEMPE, AZ · NPI 1679565519
Verified facts
What the public records show
CMS Open Payments records show Aureliano E Cifuentes, MD received $1,070.75 in general payments during 2025 across 40 reported records.
SANOFI-AVENTIS U.S. LLC accounted for 16.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Kerendia, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 291 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Soliqua 100-33 by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $179.20 | 16.7% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $103.12 | 9.6% | 4 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $101.88 | 9.5% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $94.17 | 8.8% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $91.00 | 8.5% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $79.78 | 7.5% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $55.57 | 5.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.51 | 4.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $44.31 | 4.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $40.27 | 3.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $35.47 | 3.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.53 | 2.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.31 | 2.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.29 | 2.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.72 | 1.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.21 | 1.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $15.88 | 1.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $14.82 | 1.4% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $14.81 | 1.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.37 | 1.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.99 | 1.3% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $13.54 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,070.75 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $179.20 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $103.12 | 4 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $101.88 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $94.17 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $91.00 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $55.57 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $44.31 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30.53 | 1 | 2025 |
Source payment records
|
|||||
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $25.51 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.29 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| AMS 700 Normalized: ams 700 |
Device | Boston Scientific Corporation | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 68 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 147 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 87 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
35 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
291 | 114 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
87 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
108 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
74 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
85 | 34 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
68 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 810 | 360 |
| Metformin Hcl | Metformin Hcl | 699 | 311 |
| Lisinopril | Lisinopril | 522 | 214 |
| Levothyroxine Sodium | Levothyroxine Sodium | 480 | 192 |
| Amlodipine Besylate | Amlodipine Besylate | 443 | 196 |
| Losartan Potassium | Losartan Potassium | 424 | 177 |
| Farxiga | Dapagliflozin Propanediol | 291 | 114 |
| Tamsulosin Hcl | Tamsulosin Hcl | 288 | 127 |
| Gabapentin | Gabapentin | 248 | 115 |
| Famotidine | Famotidine | 247 | 111 |
| Celecoxib | Celecoxib | 243 | 104 |
| Alendronate Sodium | Alendronate Sodium | 224 | 111 |
| Simvastatin | Simvastatin | 216 | 85 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 208 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 203 | 85 |
| Omeprazole | Omeprazole | 196 | 91 |
| Furosemide | Furosemide | 177 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 176 | 78 |
| Jardiance | Empagliflozin | 147 | 56 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 147 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 147 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 65 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 140 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 136 | 63 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 118 | 42 |
| Azithromycin | Azithromycin | 114 | 103 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 112 | 48 |
| Glipizide | Glipizide | 111 | 44 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 110 | 53 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 109 | 49 |
| Potassium Chloride | Potassium Chloride | 109 | 44 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 108 | 52 |
| Trulicity | Dulaglutide | 108 | 26 |
| Sertraline Hcl | Sertraline Hcl | 100 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 47 |
| Carvedilol | Carvedilol | 98 | 36 |
| Ibuprofen | Ibuprofen | 98 | 51 |
| Oxycodone Hcl | Oxycodone Hcl | 98 | 40 |
| Pioglitazone Hcl | Pioglitazone Hcl | 95 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 94 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 38 |
| Trazodone Hcl | Trazodone Hcl | 90 | 36 |
| Kerendia | Finerenone | 87 | 28 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 85 | 34 |
| Donepezil Hcl | Donepezil Hcl | 84 | 48 |
| Alprazolam | Alprazolam | 79 | 23 |
| Finasteride | Finasteride | 76 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 74 | 46 |
| Eliquis | Apixaban | 74 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 71 | 61 |
| Fenofibrate | Fenofibrate | 71 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 71 | 22 |
| Gemtesa | Vibegron | 68 | 21 |
| Ozempic | Semaglutide | 68 | 23 |
| Valsartan | Valsartan | 65 | 26 |
| Januvia | Sitagliptin Phosphate | 63 | 27 |
| Cephalexin | Cephalexin | 62 | 46 |
| Meloxicam | Meloxicam | 61 | 33 |
| Enalapril Maleate | Enalapril Maleate | 60 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 27 |
| Montelukast Sodium | Montelukast Sodium | 59 | 30 |
| Atenolol | Atenolol | 56 | 24 |
| Fluconazole | Fluconazole | 56 | 34 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 55 | 21 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 53 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 22 |
| Pregabalin | Pregabalin | 51 | 17 |
| Buspirone Hcl | Buspirone Hcl | 50 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 31 |
| Clonazepam | Clonazepam | 48 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 23 |
| Liothyronine Sodium | Liothyronine Sodium | 47 | 18 |
| Spironolactone | Spironolactone | 47 | 20 |
| Testosterone Cypionate | Testosterone Cypionate | 46 | 18 |
| Ezetimibe | Ezetimibe | 45 | 22 |
| Rybelsus | Semaglutide | 45 | 26 |
| Tramadol Hcl | Tramadol Hcl | 44 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | 15 |
| Lovastatin | Lovastatin | 42 | 18 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Lactulose | Lactulose | 40 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 17 |
| Allopurinol | Allopurinol | 39 | 27 |
| Chlorthalidone | Chlorthalidone | 39 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | 25 |
| Metformin Hcl Er | Metformin Hcl | 39 | 17 |
| Valacyclovir | Valacyclovir Hcl | 39 | 13 |
| Glimepiride | Glimepiride | 38 | 21 |
| Tradjenta | Linagliptin | 38 | 13 |
| Diltiazem Hcl | Diltiazem Hcl | 37 | suppressed |
| Memantine Hcl | Memantine Hcl | 37 | 16 |
| Clonidine Hcl | Clonidine Hcl | 36 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Clotrimazole | Clotrimazole | 35 | 28 |
| Prednisone | Prednisone | 35 | 23 |
| Prolia | Denosumab | 35 | 23 |
| Terbinafine Hcl | Terbinafine Hcl | 34 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 31 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | 11 |
| Linzess | Linaclotide | 32 | 13 |
| Hydrocortisone | Hydrocortisone | 30 | 15 |
| Azelastine Hcl | Azelastine Hcl | 29 | 20 |
| Metolazone | Metolazone | 29 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 17 |
| Fenofibrate | Fenofibrate,micronized | 27 | 15 |
| Humalog | Insulin Lispro | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | 12 |
| Doxepin Hcl | Doxepin Hcl | 26 | 14 |
| Meclizine Hcl | Meclizine Hcl | 26 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | 13 |
| Pilocarpine Hcl | Pilocarpine Hcl | 25 | suppressed |
| Ssd | Silver Sulfadiazine | 25 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | 14 |
| Dapagliflozin | Dapagliflozin Propanediol | 24 | 24 |
| Ketoconazole | Ketoconazole | 24 | 18 |
| Nifedipine Er | Nifedipine | 24 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | 14 |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 22 | 16 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 22 | 11 |
| Latanoprost | Latanoprost | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | 15 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 21 | 20 |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 20 |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Metronidazole | Metronidazole | 18 | 13 |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | 18 |
| Sucralfate | Sucralfate | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 15 |
| Promethazine Hcl | Promethazine Hcl | 16 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 15 |
| Candesartan Cilexetil | Candesartan Cilexetil | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 14 |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 15 |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Acetic Acid | Acetic Acid | 14 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Progesterone | Progesterone, Micronized | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,070.75 · 40 records | SANOFI-AVENTIS U.S. LLC | AIRSUPRA, AMS 700, Dexcom G6 Transmitter, Epclusa, FREESTYLE LIBRE 3, GEMTESA, GIMOTI, GIVLAARI, INJECTAFER, INSPIRE, JARDIANCE, KEVEYIS, Kerendia, Korlym, Leqembi, NURTEC ODT, OTEZLA, PROCLAIM, RECORLEV, REPATHA, REXULTI, SHINGRIX, TRELEGY ELLIPTA, TZIELD, XIFAXAN, Yeztugo, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error